INTRODUCTION
N OVEL BACTERIAL TARGETS are becoming increasingly desirable for antimicrobial screening due to the high propensity for pathogenic strains to develop resistance to current treatments. One of the more problematic organisms is methicillin-resistant Staphylococcus aureus (MRSA), first reported in 1961. 1 Since the early 1960s, MRSA has spread from European hospitals to the United States, where it currently accounts for 25% of nosocomial infections. 2 The control of MRSA is confounded by a multidrugresistant phenotype that makes it resistant not only to β-lactams but also to other classes of antibiotics, including aminoglycosides, macrolides, tetracyclines, and quinolones. 3 Reports of community-acquired MRSA infections are increasing, [4] [5] [6] [7] making it a key organism for novel chemotherapies.
A modern approach for discovering new classes of compounds with modes of action different from current therapies is to screen hitherto unexploited molecular targets. 8, 9 Large-scale genomic sequence comparisons have allowed rapid identification of open reading frames (ORFs) that are highly conserved in pathogenic organisms but are absent in eukaryotes. This information allows for the rational choice of targets that are selective for bacteria and may lead to the identification of broad-spectrum agents [9] [10] [11] , potentially reducing the risk of mechanism-based toxicity. Recently identified novel targets include virulence gene products, membrane transporters, cofactor biosynthesis, chorismate biosynthesis, and fatty acid biosynthesis. 8, 9, 12 The key criterion that each of these targets possesses is that they have been shown to be indispensable for bacterial cell viability under laboratory conditions or during an infection. The determination of essentiality via wide-scale genetic screening in combination with genomic sequence comparisons has unveiled numerous essential ORFs that are functionally uncharacterized. 9, 13, 14 According to Chan et al., 8 approximately 30% of the genes in a bacterial genome are annotated as unknown, and at least 20% of these are ubiquitous to bacteria. One such ORF, designated YihA, was identified as having a nonviable phenotype upon chromosomal deletion in Escherichia coli and Bacillus subtilis. 13 This analysis demonstrated the essentiality of YihA in both a gram-negative and a gram-positive organism 13 and distinguished it as a novel antimicrobial target.
To overcome the difficulty associated with screening a protein of unknown function, we chose to use high-throughput affinity capillary electrophoresis (ACE) to identify compounds that bound YihA. Advances in high-resolution capillary electrophoresis (CE) allow for enhanced separation and detection. The principle behind the ACE assay is that in solution, the target migrates through the capillary when an electric field is applied. After a ligand binds to the target, it imparts a change in charge or conformation, resulting in a shift in its electrophoretic mobility. Custom software tracks the ACE migration pattern, and the resulting change in mobility designates the compounds as a hit. Using laser-induced fluorescence (LIF), binding interactions of labeled target or ligand can be detected at low concentrations (nM to pM), allowing the identification of compounds at low abundance, as well as a wide range of binding strengths not achievable by other bioscreening assays. Moreover, because the assay directly detects the binding of the compounds, little information is required about the biological function of the target. Using YihA as the protein target and highthroughput CE as the screening method of choice, a smallmolecule library of 44,000 compounds was screened with the objective of finding novel chemical structures with broad-spectrum activity against resistant pathogenic bacteria.
MATERIALS and METHODS

Cloning and expression
Genomic sequences available from public databases 15 were used to design primers for amplification of the entire ORF encoding YihA from E. coli MG1655. The primers were designed to include NdeI and XbaI restriction sites, an optimized ribosome binding site, and a C-terminal 6X histidine tag (5′-CTAGTCTAGATTAATGATGATGATGATGATGTTCGCCGT CCTGCGTTTCTTCTAC-3′, 5′-CCGGAATTCTAAGGAGG AATTAACCATGTTGACTAATTTGAATTATCAACAGACG-3′). The PCR product was cloned into pBAD18-Kan (ATCC, Manassas, VA) for inducible expression using arabinose. The sequenced clones were grown to OD 600 nm of 0.8 and induced with 0.2% arabinose for 3 h at 37°C. The cells were harvested and the cell pellets frozen at -80°C.
Protein purification
The cell pellets were resuspended in buffer A (50 mM sodium phosphate [pH 6.0], 0.3 M NaCl, 10% glycerol, 20 mM imidazole, 1% Triton X-100) and lysed by sonication. The suspension was spun at 20,000g, and the clarified supernatant was loaded onto nickel-NTA resin (Qiagen, Inc., Valencia, CA). The protein was eluted with buffer A containing 0.35 M imidazole; dialyzed extensively against 50 mM Tris (pH 7.5), 100 mM NaCl, and 10% glycerol; and frozen in aliquots at -80°C. Coomassie staining of a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel revealed that the protein was > 90% pure and migrated as a single band of molecular weight ca. 23,000 Da.
Protein labeling
The protein was amine labeled with fluorescein. Briefly, YihA was buffer exchanged into 30 mM HEPES/NaOH (pH 7.5), 20 µM β-mercaptoethanol, 0.1% CHAPS, and 150 mM NaCl using a Centri-Sep gel filtration column per the manufacturer's instructions (Princeton Separations, Inc., Adelphia, NJ). A final dye (Fluorescein-5-EX, succinimidyl ester dye; Molecular Probes, Eugene, OR) to protein ratio of 5:1 was used, and the YihA was labeled on ice for 1 h. The reaction was terminated with the addition of NH 4 Cl. Excess free dye was removed by exchange of the reaction into storage buffer (20 mM Tris/AcOH [pH 7.5], 150 mM NaCl, 0.1% CHAPS, 5 mM dithiothreitol [DTT]) through 2 successive Centri-Sep gel filtration columns. Glycerol was added to a final concentration of 50%, and the fluorescein-labeled protein was stored at -20°C.
Compound screening format
For primary screening, mixtures of 4 compounds per well were prepared in 96-well microplates at concentrations of 2 mM each in 100% DMSO. Compounds were diluted into an ACE running buffer to 10 µM for each final screening concentration (2% DMSO). Positive wells were deconvoluted into individual compounds in 96-well plates and screened at 10 µM (2% DMSO) to determine which compound from the mixed sample was the binding hit. All individual compounds that were scored as a binding hit in the deconvolution screen were resupplied and screened for confirmation of results.
Instrumentation
The ACE assay was developed on a Beckman PACE 5000 CE system. High-throughput screening of compounds was performed on the Gemini CE system developed at Cetek Corporation (Marlborough, MA) using laser-induced fluorescence (ex = 488 nm/em = 520 nm) of the labeled protein. The Gemini is a proprietary CE system combining a robotic high-throughput pipetting station with 4 capillaries and LIF detectors. The capillaries are fused silica, 10 cm in length with a volume capacity of 1 µL. The inner capillary wall was coated with a proprietary, neutral polymer to minimize protein adsorption and electrosmotic flow. The sensitivity of the Gemini allows the convolution of up to 10 compounds per injection with an injection volume of 10 nL. The throughput of the Gemini for the assay was 240 samples/h (4 compounds/injection), including a 1-min capillary rinse between each sample injection. The LIF detector is a multiunit module composed of (1) an Argon laser that excites the labeled protein through a window cut in the surface of the capillary; (2) various lens and thin-film interference filters, which collect the emission energy from the labeled protein; and (3) a miniature photomultiplier tube (PMT) module, which generates an analog voltage proportional to the amount of fluorescent light energy produced by the labeled protein passing through the capillary window. The analog signal from the PMT is then converted to a digital signal and displayed as an electropherogram. The ACE assay was run at 600 V/cm with a 15°C capillary temperature. Software to analyze ACE electropherograms was designed and written specifically for the Gemini instrumentation.
ACE assay conditions
A target cocktail was prepared that contained labeled YihA diluted to a final concentration of 5 nM in sample buffer (Tris/AcOH, pH 8.0, with 3 mM MgCl 2 ). 5 ng/mL of a 9-mer fluorescein-labeled synthetic peptide (FLP) was included in the sample buffer as an internal standard. The capillary running buffer was TABS/Tris (pH 8.5) with 3 mM MgCl 2 . A final concentration of 2% DMSO was added to the running buffer for rinses between injections, for negative controls, and for positive controls in which capillaries contained either guanosine 5′-diphosphate (GDP) or guanosine 5′triphosphate (GTP). A 10-µM final concentration of each compound, in mixtures or individually, was added to the running buffer and then introduced into the capillary. Target cocktail was injected into the capillary and run under the above ACE conditions. Controls were run every 16 samples. Compounds were scored as positive or negative for target binding by comparing the profile in the presence of the compound to the profile of controls. A compound, which generated a qualitative change in the ACE profile that was defined as a distinct, reproducible change in the physical appearance of the protein profile or a change in the migration rate of more than (approximately) 10% when compared to DMSO controls, was scored as a "hit."
Cheminformatics analysis
Molecular descriptor sets were generated for each unique chemical structure using the QuaSAR package (Chemical Computing Group, Inc., Montreal, Canada) and proprietary cheminformatics algorithms. The range of values generated by each descriptor was mapped linearly onto a scale of 0 to 1 and was hierarchically clustered using complete linkage with an Euclidean metric (OmniViz, version 3.6, Maynard, MA) and visualized via TreeScape. The following values were used: a_acc, number of hydrogen bond acceptor atoms; a_base, number of nonbasic atoms; a_don, number of hydrogen bond donor atoms; AlogP, the octanol/ water partition coefficient and molar refractivity; B_1_rotN, number of rotatable single bonds; b_rotN, number of rotatable bonds; b_rotR, fraction of rotatable bonds; diameter, largest value in the Petitjean distance matrix; Fcharge, total charge of molecule; Mo-lecular_weight, atomic weight, including implicit hydrogens; NplusO_Count, number of nitrogen plus oxygen atoms; Num_H_Acceptors, number of hydrogen acceptors atoms, Num_H_Donors, number of hydrogen bond donors; Polar Surface Area, polar surface area; radius, Petitjean radius; SlogP, log of octanol/water partition coefficient based on an atomic contribution model; TPSA, total polar surface area calculated from group contributions; vdw_area, area of van der Waals surface; vdw_vol, van der Waals volume; vsa_acc, sum of the van der Waals surface areas of pure hydrogen bond acceptors; vsa_hyd, sum of the van der Waals surface area of hydrophobic atoms; and vsa_pol, sum of van der Waals surface area of polar atoms.
Antibacterial screening
Compounds were tested at 50 µM for inhibition of growth of MRSA ATCC 29213, Streptococcus pneumoniae ATCC 49619, E. coli ATCC 25922, and E. coli strain EW1b (E. coli, Genetic Stock Center 5634) in 100 µL of cation-adjusted Mueller Hinton broth with 1% DMSO at 35°C. After overnight incubation, the absorbance at 600 nm was measured, and values less than 0.05 were considered as 100% inhibition. To determine the minimal inhibitory concentration (MIC) of compounds of interest, 2-fold dilution series were tested according to guidelines from the National Committee for Clinical Laboratory Standards (NCCLS) for microdilution susceptibility testing. 16 
RESULTS AND DISCUSSION
ACE assay development
Labeled YihA protein was tested in the ACE assay under various conditions and with different buffers and additives to obtain the clearest and most reproducible protein profile. The optimal ACE target profile was obtained using conditions in which the sample buffer consisted of Tris/AcOH (pH 8.0) with 3 mM MgCl 2 and running buffer TABS/Tris (pH 8.5) with 3 mM MgCl 2 . The optimal electrophoresis conditions were 600 V/cm with 15°C capillary temperature. DTT (1 mM) was included in the buffers to minimize nonspecific interactions of compounds with the target protein. MgCl 2 was included as a required cofactor. To demonstrate the stability and reproducibility of the ACE profile of the labeled YihA under these conditions, the protein was injected into the capillary 10 successive times over a 1-h period. The capillary was rinsed with running buffer for 1 min between injections. Figure 1 shows ACE profiling at 0-, 15-, 30-, 45-, and 60-min injection times. The labeled protein is identifiable as a major peak that migrates past the detector at~2.4 min. The profile and migration rate is stable over 4 h (data not shown). The peak migrating past the detector at~2.1 min is free dye, and the peak migrating past the detector at~2.7 min is the FLP internal standard.
To demonstrate the capacity of the ACE assay to detect binding between labeled YihA and known binders GDP and GTP, 17 the target was electrophoresed in running buffer containing GDP or GTP. Under this format, the ACE assay would be expected to detect binding interactions between target and ligand with IC 50 values of 100 µM and lower. YihA binds GTP and GDP with an equilibrium dissociation constant (K d ) of 27 and 2.3 µM, respectively. 17 Increasing concentrations (1-200 µM) of either GDP or GTP were added to the running buffer containing 2% DMSO to demonstrate the ACE profile for a concentration-dependent shift. Figure 2 shows that the protein profile shifted, migrating faster in the presence of both GDP and GTP in a concentration-dependent manner, indicating that labeled YihA protein binding is detectable in the ACE assay. To demonstrate that the binding is specific to GTP and GDP, addition of 200 mM ATP was also tested and resulted in no change in the ACE profile (data not shown).
Screening campaign
The ACE assay was used to screen 44,440 synthetic small molecules with 4 compounds per well. A total of 115 wells from the primary screen contained binding hits that represented both qualitative changes and migration rate changes in the protein profile. Wells containing binding hits were deconvoluted. Testing of the individual compounds resulted in 115 (0.26%) initial binders. From these 115 hits, 112 compounds were available in sufficient quantity to perform a second screen to confirm binding to the target. After retesting the 112 compounds, 85 (76%) were designated as confirmed binding hits. The total consumption of target protein for the entire project from assay development through final compound screening was 0.2 mg. Collectively, these results show that the ACE assay results in a low primary hit rate and a high confirmation hit rate.
Quality of compounds
To assess the quality of the compounds designated as initial binders, we analyzed 115 compounds for their desirability as drug-like molecules using Lipinski's rules. 18 Of the compounds, 105 had 5 or fewer hydrogen bond donors, 98 compounds had a nitrogen plus oxygen atom count less than 10, 46 had LogP values less than 5, and 58 had molecular weights less than 500 Da. Taken together, these data suggest that the molecules designated as binders possess chemical qualities desirable in small-molecule drugs. To characterize the chemical diversity of the compounds, we generated molecular descriptors using QuaSAR and mapped the computed values for each descriptor on a scale of 0 to 1. The descriptors were clustered using hierarchical clustering with an Euclidean metric and visualized using the TreeScape feature of OmniViz (Maynard, Massachusetts). Inspection of the patterns in Figure 3 demonstrates that the 115 binding hits (rows) possess diverse chemical properties (columns) that are represented by variations of red and blue. The ACE assay identified compounds of numerous molecular classes, with some having multiple members leading to a preliminary structure-activity relationship (SAR) analysis. The hits were grouped via visual inspection into 15 unique structural templates, with each having 2 or more members, and the remaining 40 compounds were represented as singlets. Inspection of the structures did not provide insight to the biological function of YihA because none of the structures were similar to known ligands of other proteins.
Antibacterial activity
Compounds identified as YihA binders by the ACE assay were tested for the ability to inhibit bacterial growth of clinically important pathogens. From the list of 115 initial compounds that bound YihA, only 107 compounds were available in sufficient quantity to test for biological activity. The compounds were tested for antimicrobial activity against S. aureus (MRSA) ATCC 29213, S. pneumoniae ATCC 49619, E. coli ATCC 25922, and E. coli strain EW1b. Approximately 75% (80 compounds) inhibited the growth of 1 or more organisms at a concentration of 50 µM. Sixty-six compounds were active against MRSA, 68 against E. coli strain EW1b, 55 against S. pneumoniae ATCC 49619, and 14 against E. coli ATCC 25922. Fifty compounds were found to inhibit both S. pneumoniae and MRSA. Of the 66 compounds that inhibited MRSA and the 55 that inhibited S. pneumoniae, 58 and 50, respectively, also inhibited 1 or more of the E. coli strains. The ability to inhibit gram-negative and gram-positive organisms is a highly desirable feature. To determine the MIC for each compound, we tested 58 of the compounds with antimicrobial activity as 2-fold serial dilutions against each of the organisms. Twenty-one compounds exhibited an MIC at or below 12.5 µM, which is approximately 5 µg/mL for a compound of 400 Da. Importantly, low antibacterial activity was observed against clinically relevant strains that exhibit problematic resistance mechanisms. Furthermore, the identification of compounds with low MICs early in the discovery process allows for initiation of experiments that tie target and activity together (i.e., selection of resistant mutants). Ongoing testing will reveal whether these molecules possess the low mammalian cytotoxicity and pharmacokinetic/pharmacodynamic properties to serve as starting points for lead optimization.
CONCLUSIONS
High-throughput CE was used to identify drug-like molecules that bound a novel protein target and that possess antimicrobial activity against multidrug-resistant pathogenic bacteria. The advent of wide-scale genomic sequencing has provided a wealth of unexploited potential antibacterial targets, but the understanding of their biological activities is still preliminary. We used the ACE assay to rapidly screen compounds against these novel antimicrobial targets in order to identify molecules that bind. In the example of YihA, 2 substrates-GTP and GDP-were identified based on conserved binding motifs within the amino acid sequence and subsequently used to validate the ACE assay. When a known substrate is not available, the target can still be screened since binding hits are directly visualized, unlike standard screens that rely on competitive displacement of a known ligand.
The ACE assay is also valuable for screening known targets and ligands. The assay detects interactions of compounds anywhere on the target, thereby identifying compounds that may be missed in a standard competitive assay (i.e., compounds that bind to clefts or pockets important for protein-protein interactions and unidentified ligands). Targets present in multiple active states (e.g., multimers, phosphorylated, etc.) can be visualized and screened differentially. The ACE assay can be readily applied to targets and ligands that do not alter substrates or liberate products measurable by traditional techniques or standard assay methodologies. Furthermore, the ACE assay conditions can be adjusted to detect binders of various affinities. In general, hits discriminated as weak binders have a k d ≥ 100 µM, moderate binders have a k d ≥ 10 µM, and strong binders have a k d ≥ 10 nM. Also, the ACE-identified binders can be titrated, providing an ACE-IC 50 value for relative affinity ranking. Finally, the speed (minutes per assay) and minute amount of samples required (0.5 µL per assay, 1 ng of target per assay) make it ideal for hard-to-purify and unstable targets, as well as for chemical libraries of limited mass and volume. Collectively, these results show that the ACE assay results in a low primary hit rate and a high confirmation hit rate and demonstrates the specificity, efficiency, and speed with which the ACE assay can detect binding hits to a target protein.
